Targeting Jumonji enzymes in small cell lung cancer

Jumonji KDM4A drives targetable oncogenic programs in small cell lung cancer

NIH-funded research Ut Southwestern Medical Center · NIH-11310111

Researchers are trying drugs that block Jumonji enzymes to slow or overcome treatment-resistant small cell lung cancer.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUt Southwestern Medical Center NIH-funded
Lab location1 site (Dallas, United States)
Project IDNIH-11310111 on NIH RePORTER

What this research studies

This project uses laboratory cells and animal models to test new drugs that block Jumonji family enzymes thought to drive small cell lung cancer. The team has developed Jumonji enzyme inhibitors with proven effects in animals and will explore using them as first-line therapy or as second-line options after chemotherapy fails. They will also test combinations with other drugs, such as mTOR inhibitors, guided by observed tumor gene activity. The goal is to find approaches that work against tumors that quickly become resistant to current treatments.

Who could benefit from this research

Good fit: People with a diagnosis of small cell lung cancer, especially those whose tumors have become resistant to standard chemotherapy, would be the most relevant candidates.

Not a fit: Patients with non-small cell lung cancers or tumors not driven by Jumonji-related biology are unlikely to benefit from these specific inhibitors.

Why it matters

Potential benefit: If successful, this work could lead to a new targeted treatment option for people with small cell lung cancer, including cases that are resistant to standard chemotherapy.

How similar studies have performed: Preclinical studies in cells and animal models support targeting Jumonji enzymes, but these inhibitors have little established track record yet in human small cell lung cancer trials.

Where this research is happening

Dallas, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.